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Abstract Atherosclerosis with its manifestations and asso-
ciated diseases is a main cause of morbidity and mortality
in industrial countries. The pathomechanisms underlying
atherosclerosis are complex and comprise exogenous
factors as well as genetic predisposition. Beyond the well-
defined risk factors for the development of atherosclerosis,
obstructive sleep apnoea (OSA) merits more and more
attention. A growing body of evidence has associated OSA
with vascular pathologies. Although the exact mechanisms
involved are not known, the occurrence of intermittent
hypoxia typical for OSA may lead to oxidative stress,
inflammation, metabolic and neural changes which in turn
are responsible for vessel dysfunction underlying athero-
sclerosis. It has been demonstrated that therapy with
continuous positive airway pressure (CPAP) plays a vaso-
protective role. This review summarises data resulting from
epidemiological and clinical studies with emphasis on the
possible mechanisms linking OSA with atherosclerosis,
predictive biomarkers helping identify OSA patients at high
cardiovascular risk and personalised treatment approaches.
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Introduction
Atherosclerosis is an inflammatory and systemic disease
[1–3]. A key process that initiates the development of
atherosclerosis is an endothelial dysfunction, followed by
lipid accumulation, the recruitment of macrophages and
T-lymphocytes as well as the migration and proliferation
of smooth muscle cells in the vascular wall. Additionally,
the regeneration potential of endothelial progenitor cells
is diminished because of their reduced number and
impaired function [2]. The resultant impaired vasorelax-
ation and the expansion of the vascular wall impede the
laminar blood stream, which promotes the thrombus
formation. The consequent plaque rupture and the activat-
ed coagulation system may lead to complete stenosis of an
affected vessel with consecutive infarction of the corre-
spondent tissue [3]. Besides known main risk factors for
development of atherosclerosis such as hypertension,
diabetes mellitus, hypercholesterolemia, nicotine abuse,
obesity, age and male sex, sleep apnoea syndrome have
been reported to have an independent negative impact on
the vascular structure and function.
The obstructive sleep apnoea (OSA) is characterised by a
repetitive partial or complete collapse of upper airways during
sleep terminated by arousals with consecutive repetitive
hypoxia/reoxygenation phases. In contrast to central apnoea
syndrome, the obstructive one is associated with inefficient
breath efforts [4–9]. The obstructive sleep apnoea syndrome
is defined as more than five apnoeas (no breath flow for
more than 10 s)/hypopnoea (reduced breath flow) per hour
(so called apnoea/hypopnoea index: AHI) in polysomnog-
raphy accompanied by the following symptoms: loud
snoring, breathing stoppage, nocturia, headache, excessive
daytime sleepiness and deficits in memory and attention with
subsequent risk of accident by day. According to the actual
data, about 20% and 7% of adults suffer from mild OSA
(5/h<AHI<15/h) and moderate to severe OSA (AHI>15/h),
respectively. The nocturnal hyperpressure treatment, so-called
CPAP (continuous positive airway pressure) ventilation is the
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gold-standard therapy of OSA. It consists in creating of
pneumatic track that avoids the collapse of the upper airways.
However, a relevant number of patients does not tolerate
CPAP therapy [10], which implicates necessity of searching
for alterative therapy options. Moreover, it is not clear, which
group of OSA patients should be treated. It seems that the
genetic predisposition which influences the extent of
vascular responses to OSA-related pathological changes
and coexistence of independent cardiovascular risk factors
determine patients at particularly high cardiovascular risk.
Because of that, the identification of such patients is one of
the most important issues when deciding about OSA therapy.
The estimation of individual risk constellation should be a
basis for an optimal personalised OSA treatment.
Possible pathomechanisms linking OSA
with atherosclerosis
A growing body of evidence associates OSA with develop-
ment of atherosclerosis [4–9]. A key phenomenon which is
believed to initiate the atherosclerotic vessel changes is the
intermittent hypopnoea-related disturbance of vascular
micromilieu. Because OSA is often attended by other
comorbidities which are also risk factors for atherosclerosis
formation, it is sometimes difficult to understand the
exclusive impact of OSA on vascular diseases. Nevertheless,
a lot of controlled, methodically excellent studies have
demonstrated that different neural, vascular, mechanic,
inflammatory and metabolic mechanisms discussed below
may be activated in OSA (Fig. 1):
– Neural activity: stimulation of sympathetic nerves with
consequent release of catecholamine substances in the
blood plasma and the urine [11].
– Vascular changes: overproduction of vasoconstrictors like
endothelin in relation to reduced release of vasorelaxants,
such as NO [12–14]; detection of elevated oxidative
stress [15], reduced endothelium-dependent vasodilata-
tion due to impaired function of endothelial cells [16].
– Mechanical factors: fluctuation of intrathoracic pressure
via increase in blood pressure may enhance shear stress in
the vessel wall with subsequent diastolic dysfunction [17].
– Inflammatory mediators: cytokines and adhesion mole-
cules attract leukocytes to the endothelial layer, which
promotes atherosclerosis in OSA [18–20]. Elevated
inflammatory markers, such as C-reactive protein
(CRP), serum amyloid A were demonstrated to be
negative predictor markers for cardiovascular endpoints
[21, 22]; the CRP levels were increased among children
with OSA, irrespective of body weight [23]; other study
showed high CRP concentration only in obese OSA
patients [24].
– Circulating endothelial progenitor cells as regeneration
capacity marker are reduced in OSA patients [25]. In
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Fig. 1 Pathophysiological interactions between OSA and atheroscle-
rosis. The OSA-associated effects (top) initiate different pathomechan-
isms (left) that contribute to the development of atherosclerosis
(down). Defined risk factors (right) augment the atherosclerotic
changes underlying vascular diseases (down)
40 EPMA Journal (2011) 2:39–47
cells increases as indicator for endothelial dysfunction
[26, 27]. The last one correlates positively with the AHI
degree [28].
– Hypercoagulability: elevation of fibrinogen, haematocrit,
plasminogen activator inhibitor-1 and platelet aggregation
[7, 29].
– Metabolic changes: obesity is closely associated with
OSA. It was described as a cause of OSA, but it can
also be worsen by OSA. The patients with new
diagnosed OSA had a significant weight increase 1 year
prior diagnosis of OSA compared to similar adipose
patients without OSA [30]. Moreover, the CPAP
therapy induces fat redistribution with reduction of
subcutaneous and visceral fat [31]. Many studies have
linked obesity to oxidative stress and inflammation
underlying endothelial dysfunction. However, the
presence of OSA in these studies was not systemat-
ically excluded. Recently, it has been shown that
OSA rather than obesity may be predominantly
responsible for increased oxidative stress, inflamma-
tion and endothelial impairment [32].
The metabolic deregulation in OSA may be connected to
the impaired leptin secretion. The increased levels of leptin
in OSA in comparison with weight-adjusted patients
without OSA may influence the breath control centre.
Additionally, leptin may enhance the rate of cardiovascular
events via stimulation of sympathetic activity and platelet
aggregation [33].
Moreover, the appetite and body fat regulators such as
neuroleptid G and ghrelin are upregulated in OSA [34].
The OSA patients suffer often from metabolic syndrome
that comprises obesity, hypertension, increased levels of
triglycerides and glucose and decreased levels of HDL-
cholesterol [35, 36]. Insulin resistance and diabetes melli-
tus, irrespective of obesity, are related to OSA degree [37,
38]. Additionally, hypoxia-induced insulin resistance has
been demonstrated in an animal model [39]. Moreover,
hypertension is widely accepted effect of OSA [4–9].
The most of the described pathomechanisms in OSA are
positively influenced by CPAP therapy [4–9, 25, 28].
Epidemiological and clinical studies associating OSA
with atherosclerotic disease
OSA is associated with coronary heart disease, myocardial
infarction, ischaemic brain infarction, aorta dissection,
hypertension, heart failure, erectile dysfunction, atrial
fibrillation and sudden cardiac death. It is difficult to
answer if OSA alone can act atherosclerotic, because the
most OSA patients have additional atherosclerotic risk
factors such as obesity, hypertension, hypercholesterolemia,
insulin resistance and hyperglycaemia.
However, some animal and human studies attempted to
demonstrate the direct link between OSA and atherosclerosis.
Atherosclerosis could be induced in a mouse model of
hypoxia on a cholesterol rich diet [40]. Moreover, the patients
with OSA have increased intima-media thickness (IMT) of a
carotid artery, enhanced pulse wave velocity (PWV) between
carotid and femoralis artery [41] and increased coronary
artery calcification in an electron beam tomography (EBCT)
[42]. The above parameters are early markers of atheroscle-
rosis. A small study could also show a reduction of IMT and
PWV under CPAP therapy [43]. However, there are
discrepant data concerning OSA and early atherosclerotic
parameters, namely some studies could not demonstrate any
association between OSA and IMT [44].
Impact of OSA on coronary artery disease/myocardial
infarction
The prevalence of OSA in coronary artery disease is about
two to three times higher compared to similar population
without cardiovascular diseases. Oppositely, one can find
OSA in 31–50% patients with angiographic documented
coronary artery disease [4–9]. Although further studies
have also demonstrated an association between OSA and
coronary artery disease (Table 1a), their data are limited by
study design with small patient number and lack of controls
[45–52].
The most important prospective observational study by
Marin et al. demonstrated that patients with an untreated
severe OSA suffer more frequently from myocardial
infarction and stroke than patients without OSA in a time
frame of 10 years [48]. Additionally, the CPAP therapy
could prevent the above vascular endpoints in the study.
However, also this study must be interpreted carefully,
because the results of non randomised behavioural studies
can not always be confirmed in subsequent randomised
studies. This fact depends for example on higher health
awareness and/or better compliance of patients who accept
CPAP therapy.
In contrast to the study of Martin et al., a community-
based prospective cohort study of the cardiovascular
consequences of OSA [53] demonstrated that the associa-
tion of OSA with incident coronary heart disease after
adjustment for other risk factors is much weaker and of no
statistical significance. These discrepancies could be
explained by older age of the cohort, as OSA-related
cardiovascular risk decreases with age. Another finding of
Gottlieb et al. was that OSA is a significant independent
predictor of incident heart failure in men but not in women
[53]. However, it is not clear, if sex differences may reflect a
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protective effect of a female sex against cardiovascular risk
or may be only a result of a statistical underestimation
because of lower prevalence of women with severe OSA and
later age of onset of OSA in women than in men.
The positive influence of CPAP therapy on cardiovas-
cular endpoints was shown in further studies [54–58
Table 1b]. It was demonstrated that an effective CPAP
therapy can reduce nocturnal cardiac ischemia/ST-segment
elevations by cardiologic patients [59].
Unfortunately, OSA appears to be strongly under
diagnosed in patients with myocardial infarction, which
probably results from persistent low awareness of OSA as a
potential risk factor in cardiovascular patients [60].
OSA as a risk factor for ischaemic brain infarction
Sleep-associated disorders can be found in approximately 2/3
cases of ischaemic brain infarction; while obstructive sleep
apnoea may be responsible for onset of ischaemic brain
infarction, the central one can be an effect of stroke [61]. The
genesis of OSA-associated ischaemic insult is probably the
result of multiple factors: atherosclerotic plaques in brain
vessels, hypertension, thrombembolic events based on atrial
fibrillation, paradoxical embolism via enhanced right-left
shunts by persistent foramen ovale. Moreover, OSA may
disturb the cerebral autoregulation [62]. Lately, the associa-
tion between microembolisms detected in MRT and OSA has
Table 1 Review of important epidemiological studies concerning a)
OSA and b) effects of CPAP therapy in OSA. ACS - acute coronary
syndrome, AHI - Apnoe-Hypopnoe-Index, CPAP - continuous
positive airway pressure, ISR - In-Stent-Restenosis, MACE - major
adverse cardiac events, MACCE - major adverse cardiac or cerebro-
vascular events, OR - Odds-Ratio, OSA - obstructive sleep apnoea,












289 AHI≥20/h – Elevated risk for myocardial infarction: OR 2.0
Mooe et al.
2001 [43]
408 AHI>10 61 Elevated risk for death, myocardial infarction and
cerebrovascular events: OR 1.6
Shahar et al.
2001 [44]
6,424 – – Elevated risk for ischaemic brain infraction and coronary artery disease:
OR 1.6 und 1.3, in each case the highest and the lowest AHI-quartile
Marin et al.
2005 [45]
1,651 AHI>30/h 121 More frequent lethal and non-lethal cardiovascular events: OR 2.9 und 3.2
Arzt et al. 2005
[46]
2,664 AHI>20/h 48 Elevated risk for ischaemic brain infraction: OR 4.3,
no significantly elevated risk for the first event
Yaggi et al.
2005 [47]
1,022 AHI≥5 41 Elevated risk for ischaemic brain infraction/death: OR 2.0
Yumino et al.
2007 [48]





120 Elevated risk for ischaemic brain infraction: OR 2.9, no effect on
myocardial infarction or death
b) Studies with CPAP therapy
Doherty et al.
2005 [50]
168 AHI>15/h 91 Reduction of cardiovascular death: 15 vs. 19%, reduction of death/






87 Reduction of cardiovascular death, ACS, hospitalisation from
heart failure, revascularisation: OR 0.24
Marin et al.
2005 [45]
1,651 AHI>30 121 Reduction of lethal and non-lethal cardiovascular events:
OR 1.1 und 1.4 vs. healthy individuals
Martinez-Garzia
et al. 2005 [52]
95 AHI≥20/h+ischaemic
brain infarction/TIA
18 Reduction of new vascular events: 7 vs. 36%
Buchner et al.
2007 [53]
449 AHI≥5 72 Reduction of cardiovascular events (myocardial infarction, ischaemic
brain infarction, ACS, revascularisation): OR 0.36
Cassar et al.
2008 [54]




168 AHI>15/h 91 Reduction of cardiovascular death: 15 vs. 19%, reduction of death/
coronary artery disease: 18 vs. 31%, no effect on ischaemic brain
infarction
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been demonstrated [63]. A prospective study based on the
questionnaire showed that snoring may be an independent
risk factor for ischaemic insult [64]. Other studies were
mostly cross-sectional or case-controlled that included only
those patients who survived the cerebral insult [50–52, 56
Table 1]. Yaggi et al. demonstrated increased stroke rates in
OSA patients in a longitudinal study, but in contrast to Marin
et al. [48], they could not show any positive effects of CPAP
therapy on the reduction of stroke incidence [50]. The
explanation of this fact could be a low CPAP tolerance and
reduced patients’ compliance. Finally, another study
concerning OSA patients after stroke event showed that
CPAP therapy reduced the cerebral re-infarction rate as
compared to untreated patients.
Potential diagnostic biomarkers for prediction
and prevention of OSA-associated atherosclerosis
Identification of OSA patients at a significant risk for the
development of atherosclerosis is mandatory in order to
prevent or at least to delay the occurrence of the vessel
disease. It is known that similar degree of OSA severity
may induce wide spectrum of atherosclerotic changes in
different patients. It can be explained by interindividual
differences in response to intermittent hypoxia which may
mirror congenital or acquired disposition to disease or
protective and regenerative potential. In order to anticipate
if protective or deleterious mechanisms possibly predomi-
nate, several determinants have been proposed to serve as
predictive biomarkers of the disease (Fig. 2). Besides direct
changes in vessel structure and elasticity indicated by
increase in arterial stiffness, intima/media thickness and
atherosclerotic plaque volume which are already detectable
in only minimal symptomatic OSA patients and are
considered to be early markers of atherosclerosis [43, 65,
66], alternations in number and function of different blood
cells and cytokines have been examined for their utility as
biomarkers of atherosclerosis. An example of such a
biomarker may be leukotriene B4 which production is
upregulated in OSA indicating its role as an incipient
mediator of atherosclerosis [67]. A number of further
proinflammatory transcription factors and agents such as
nuclear factor kappa B (NFkB), CRP, interleukin (il)-6,
tumour necrosis factor (TNF)-alpha, intracellular adhesion
molecule (ICAM)-1, vascular adhesion molecule (VCAM)-1,
L-selectin, E-selectin, P-selectin and CD40 ligand as well as
antioxidant genes [68–79] are elevated in OSA and play an
important role in various stages of atherosclerosis. Moreover,
decrease in anti-inflammatory acting interleukin-10 plasma
levels predisposes to progression of atherosclerosis [80, 81].
Early inflammatory responses underlying atherosclerosis
may be partly triggered by lipid accumulation in arterial
wall as a result of decreased lipoprotein lipase activity found
in OSA [82]. Conversely, inflammation und oxidative stress
lead to metabolic disorders accelerating atherosclerotic
changes underlying end organ damage [83–85]. Another
OSA-associated disorder that contributes to the progression
of vessel lesions is the unbalance between vasoactive
substances such as nitric oxide (NO) and endothelin (ET)-1
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Fig. 2 Cardiovascular risk
estimation by means of
different biomarkers
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[86], partly as a consequence of the overexpression of
asymmetric dimethylarginine (ADMA) - endogenous inhibi-
tor of NO production [87] observed in OSA. Furthermore,
some studies suggested OSA-related upregulation of
hypoxia-inducible factor (HIF) 1 alpha followed by the
exaggerated release of proatherogenic substances like vascu-
lar endothelial growth factor (VEGF) and ET-1 [86, 88].
Additionally, serum amyloid A and myeloid-related protein
8/14 which are linked to augmented risk for cardiovascular
morbidity may be also elevated in OSA [22, 89]. Likewise,
cellular changes in blood may indicate later atherosclerotic
vessel alternations in OSA. For instance, an attenuated
apoptotic index of neutrophils with subsequent disturbance
of injury limiting mechanisms demonstrated in OSA may
help identify patients prone to cardiovascular pathologies
[90]. Beyond that, OSA-induced hypoxic stress enhances
invasive ability of monocytes, which may provide evidence
for a raised risk for atherosclerosis development [91].
Another phenomenon occurring in OSA which accelerates
atherosclerosis is the increased lipid accumulation in macro-
phages [92]. Lymphocyte activation with augmented cyto-
toxicity and cytokine imbalance in CD4 and CD8 T cells in
OSA may also modulate some atherogenic pathways [93].
Higher numbers of circulating endothelial (Annexin-V
positive), platelet and leukocyte apoptotic microparticles
combined with diminished endothelial progenitor cell count
indicating disturbed endothelial repair mechanisms are
believed to be further biomarkers for atherosclerosis in
OSA [94–97]. Perspectively, molecular studies on the
telomere length, which is thought to reflect cumulative
burden of oxidative stress and inflammation in OSA, may
contribute to improvement of cardiovascular risk estimation
in OSA patients [98]. Summarising, the risk stratification for
the development of atherosclerosis in OSA by means of
different biomarkers enables better monitoring of disease
dynamics and, if required, early treatment initialisation.
Standard and innovative therapy options
Once OSA has been diagnosed, the decision of therapy start
and treatment options depends on the polysomnography
results, including severity of OSA, clinical symptoms,
comorbidities and patients’ compliance. General therapy
recommendations comprise common and sleep hygienic
means, body weight reduction, physical activity, avoidance
of alcohol and nicotine, training of sleep position, intraoral
protrusion splints and operative methods. The gold standard
is CPAP therapy, however the threshold value of AH-Index
for therapy start is not known. Figure 3 shows therapeutic
procedures in OSA that have not been tested in randomised
trials and which must be optimised for individual patients.
In particular, OSA patients at elevated risk for cardiovascular
diseases benefit mostly from early diagnosis and appropriate
treatment. However, the recognition of such patients is not
easy as there are no standardised criteria for cardiovascular
risk stratification in OSA. Many biomarkers described above
have been proposed to be a useful tool for anticipation of a
vessel disease. Further randomised studies are needed to prove
their clinical relevance.
Although the mainstay of therapy in OSA is a treatment
with CPAP, the targeted therapy of concomitant, indepen-
dent of OSA cardiovascular risk factors is at least of the
same importance. Therefore, the primary and secondary
prevention of the known predisposing factors for the
development of atherosclerosis such as hypertension,
diabetes, dyslipidemia by accurate screening, efficient
therapy and frequent controls improves the effectiveness
of CPAP therapy in minimising of the atherosclerosis risk.
Since the adherence to CPAP therapy for OSA is poor [10]
and CPAP treatment does not eliminate all hypoxia-associated
risk factors for atherosclerosis [99], many study designs have
focused on the development of alternative therapies. Besides
the introduction of improved forms of positive airway
pressure therapies [100] and innovative devices such as
electrical stimulator of the hypoglossal nerve [101], different
pharmacological interventions have been tested. Based on the
hypothesis that OSA mediates its proatherogenic effects via
induction of oxidative stress, the antioxidant strategies such as
the intravenous infusion of antioxidant vitamin C in OSA
subjects have been demonstrated to improve endothelial
function [102]. Investigations in the field of the involvement
of the endothelin system in cardiovascular pathologies
associated with OSA showed the beneficial cardiovascular
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Fig. 3 Therapeutic procedures in OSA according to the degree of
OSA and accompanied symptoms and risk factors. AHI - Apnoe-
Hypopnoe-Index, CPAP - continuous positive airway pressure
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[88]. In a subgroup of patients with both OSA and
hyperlipidemia, targeting of a sterol regulatory element
binding protein (SREBP)-1, a transcription factor for lipid
biosynthesis, which is upregulated in OSA, could improve
lipid metabolism and in consequence cardiovascular progno-
sis [103]. Future studies are mandatory to prove attractive
therapy concepts such as administration of anti-inflammatory
substances, restoration of endothelial repair capacity via
treatment with endothelial progenitor cells or molecular
approaches taking into consideration genetically defined
polymorphisms for prooxidant and antioxidant enzymes
determining individual susceptibility to cardiovascular
changes in OSA.
Perspectives
Despite coexistence of not homogenous study results and
problems by establishment of a good study design because of
confusing factors, there are many convincing data demon-
strating that obstructive sleep apnoea may influence negative-
ly the development of atherosclerosis. Therefore, higher
awareness in recognising of OSA, early diagnosis and
effective therapy of OSA are indispensible elements of an
appropriate medical care, particularly in patients at cardiovas-
cular risk. Future directions comprise further studies on the
mechanisms of cardiovascular damage in OSA in order to find
new biomarkers of atherosclerosis characterised by their
simplicity, noninvasivness and combined high sensitivity
and specificity as well as to develop alternative therapy
modalities. The knowledge of individual risk factors and
different possible cardiovascular responses to the intermittent
hypoxia will help improve personalised treatment.
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